Anthony Letai received his MD and PhD at the University of Chicago, completing clinical training in Hematology and Oncology at Dana-Farber Cancer Institute. After a post-doc with Stanley Korsmeyer. Since 2004 Dr. Letai has run a laboratory at Harvard Medical School and Dana-Farber Cancer Institute to study how apoptosis can be evaded by cancer cells. Key to these studies is a novel assay - BH3 profiling. He has led efforts to translate BCL-2, BCL-XL, and MCL-1 antagonists into the clinic. These include venetoclax, a BCL-2 antagonist approved by the FDA for CLL and AML and now being tested across nearly all blood cancers. The laboratory is testing whether BH3 profiling can be used as a broad predictive biomarker to assign clinical cancer therapy.
Twitter: @ DrTonyLetai
« Go Back